IgE 免疫复合体通过 NLRC4 炎症体减轻埃索诺菲尔免疫反应
Ece Oylumlu1, Goksu Uzel1, Lubeyne Durmus1
1Molecular Biology and Genetics Department, Istanbul Technical University, Istanbul 34469, Turkey.
Mediators of inflammation
|October 27, 2023
概括
抗原特异性免疫球蛋白E (IgE) 免疫复合体 (ICs) 通过NLRC4炎症体信号传递来激活埃索诺菲尔. 这项研究揭示了IgE ICs如何影响埃索因菲尔反应,为过敏性疾病提供了洞察力.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 过敏研究 研究过敏
背景情况:
- 免疫复合体 (ICs) 调节免疫反应.
- 免疫球蛋白E (IgE) 与Th2反应和天生的免疫细胞激活有关.
- 对抗原 (Ag) 特定的IgE ICs在人类乙氨基酸调节中的作用尚未完全理解.
研究的目的:
- 通过使用EoL-1细胞系来研究卵蛋白 (Ova) -IgEICs影响欧素反应的机制.
- 探索NLRC4炎症酶和Toll-like受体2 (TLR2) 信号在IgE IC介导的氨基酸激活中的参与.
主要方法:
- 利用人类的EoL-1细胞系作为埃索诺菲尔细胞的模型.
- 用卵蛋白 (Ova) -IgE免疫复合体 (ICs) 刺激的细胞.
- 评估了NLRC4炎症组分,细胞因子 (IL-1β),颗粒蛋白 (MMP9,TIMP1,TIMP2) 和脱粒标记物 (CD63+) 的表达.
- 研究了涉及TLR2和FcεRII的信号通路.
主要成果:
- 卵子-IgE ICs通过TLR2信号传导诱导NLRC4炎症组分和IL-1β分泌.
- 通过FcεRII,IgE ICs促进了MMP9,TIMP2和ECP的mRNA表达,以及MMP9和TIMP2的蛋白质表达.
- 与TLR2连接体和Ova-IgE ICs联合刺激增加了CD63+细胞,表明与本源IgE相比增强了脱粒化.
结论:
- 卵子-IgE ICs通过NLRC4炎症体和FcεRII通路激活乙酸细胞.
- 这些发现阐明了IgE ICs对氨基细胞反应的影响机制.
- 这项研究提供了对氨基酸相关疾病 (如喘和过敏性炎症) 的见解.
相关概念视频
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
312
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
312
Allergic Drug Reactions
852
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
852
Cells of the Innate Immune Response
1.7K
The innate immune response is an immediate and non-specific response against pathogens, acting swiftly to prevent the spread of infections. The primary cells involved in this response are phagocytes and natural killer (NK) cells.
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...
1.7K
Inflammatory Response
2.1K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.1K
Antiasthma Drugs: Leukotriene Modifiers
324
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
324


